E. F. Solomayer

TL;DR: The presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer is associated with a poor prognosis.

TL;DR: The disease is significantly more stable in patients with first bone metastases than in those with first visceral metastases, and the better prognosis of patients withBone metastases is not determined exclusively by hormone receptor status.

TL;DR: The proposed classification of immunostained events is a first step towards the development of standardized immunocytochemical assays for the detection of occult micrometastatic TC in BM or blood.

TL;DR: These long-term survival data extend the survival advantage reported in previous studies with oral clodronate in breast cancer, and significant reductions in the incidence of bony and visceral metastases and improvement in duration of DFS at 36- and 55-month follow-up periods were no longer seen.

TL;DR: The potential of this technique has already been demonstrated by employing fluorescence in situ hybridization methods to measure expression of the HER2/neu gene in tissue from patients with breast carcinoma for the specific purpose of identifying those patients most likely to respond to Trastuzumab targeted therapy.